Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| through this year with a robust demand from 2023, a fully transitioned patient support services hub and the support of Ultragenyx' focused field team, we feel confident that 2024 will be another strong year for Crysvita in North America |
| In 2023, we generated significant momentum across our commercial and clinical programs that have set us up for Catalyst bridge 2024 |
| On the commercial front, we progressed international regulatory and reimbursement negotiations across our marketed products, continuing to add to new approvals and positive reimbursement decisions |
| This geographic expansion along with growing demand in our existing markets put us in position to maintain our trajectory of robust year-over-year growth |
| On the clinical side, we released new data on our key programs in 2023 and successfully advanced enrollment of our priority programs that can accelerate value creation for our company this year and in the coming years |
| We've made incredible progress across the clinical pipeline, which sets us up for a number of data catalysts this year |
| Building on the success in 2023, we expect continued strong performance across our portfolio in 2024 |
| This approval further validates the drug's clinical value and expands the addressable patient population in the EMEA region |
| So you have to -- we have to smooth it out with guidance that makes sense, but I feel good about the guidance we have and 20% growth rate should be excellent |
| Since the fracture reduction is up already at the 67% estimate rate that puts us in good position to potentially have a positive interim |
| So we're very encouraged about setrusumab in the path forward |
| Emil Kakkis Well, in the meeting there, we had really positive feedback from people because I think the extended data is continuing to show good developmental progression among the longer treated patients |
| We're trying our best to navigate guidance and give the Street numbers we feel confident in achieving |
| and European regulatory interactions give us confidence that we will be able to navigate the development path for this program |
| In Latin America, we are making steady progress in finding patients despite the lack of newborn screening in the region while expanding access for Dojolvi to more patients |
| and Canada, the demand for start forms remains strong |
| So I think we're encouraged about the progress forward on the workshop, the data we released, the data others have released tell us that we have a handle on how to treat MPS disease and particularly MPS-IIIA and that's a good thing because there hasn't been a single trend for MPS brain disease approved today |
| Last week, GTX-102 was granted priority medicine or PRIME designation by the European Medical authority based on the positive early clinical data from the long-term extension cohorts and the potential of GTX-102 to address the unmet need for our treatment in this disease |
| We Regardless of the timing, the reduction in the annualized fracture rate that we saw in the Phase II study and shared at ASBMR last year gives us confidence that we will see a clinically meaningful and statistically significant reduction in clinical fracture rate in the Phase III study |
| We're making good progress, and we feel comfortable about putting together a plan when we have our Phase II data in hand when we meet them with end of Phase II, but we're encouraged by the discussion and think there's a way forward in terms of finalizing the plan for Phase III |
| In 2023, the smooth transition and additional field resourcing helped support the growing demand for Crysvita in the U.S |
| We feel the data there should encourage the FDA to take the stand of accepting heparan sulfate as a reasonably likely to predict clinical benefit marker and start doing solid approvals in the MPS brain disease area, which if it happens, I believe, will help us move forward in other rare genetic disorders, particularly that affect the brain |
| Our discussions on an accelerated approval pathway with the FDA are ongoing, and we continue to believe there's a strong case to be made in this program |
| And so we're encouraged and there's been a number of people using the HF marker and showing similar predictive value |
| These combined efforts across our global organization generated 2023 Crysvita revenue of $328 million, which is a 17% increase compared to 2022 |
| We'll continue expanding global access to our commercial products, bringing these important therapies to more and more patients is expected to generate more than $500 million in revenue and support our path toward profitability |
| And if you look at day 254, the data looks much stronger |
| Looking ahead, we are entering 2024 in a robust financial position with $777 million on the balance sheet, including proceeds from our equity offering in the Q4 that raised $326 million |
| On GTX-102 for Angelman syndrome, data from the long-term extension cohorts Phase I/II study demonstrated clinically meaningful improvements across multiple neuro-developmental domains, including cognition, receptive communication, growth motors, behavior and fleet |
| And I think looking at 20% growth rate, I think, is I think, still excellent growth rate |
| Statement |
|---|
| And I think the efficacy data they put out has not been impressive |
| The challenge is very complicating right now, particularly for those that had safety events and another ASO to drop into a Phase III study |
| Because the problem with cornstarch is not taking cornstarch |
| For the year, net loss was $607 million or $8.25 per share |
| But I do think the negative effect, the length of time are factors, which will help reduce the risk of a placebo response clipping or impairing the results of that study |
| The problem is that each patient lives each day with a gun to its head thinking, if I forget to make cornstarch, I could die, as a horrible burden on live with and have to take something every three hours |
| Is there some buying before the winter months and before the new year? But -- and it's just something that we're always going to have to manage overall |
| But when you analyze out the fourth quarter numbers, it seems like you're already at the lower end of guidance |
| In the Phase III, though, you have to worry what you're thinking, well, what if people are optimistic |
| There are some milder but majority are severe |
| But I'm not really worried about the competitor |
| Dojolvi may be a little slower because some of the territories we just have -- we're responding to named patient sales, but I think Eric made that clear |
| So at this point, I would look at most of the patients being highly dependent on starch, having very severe phenotype and probably in the greatest need and the most danger from that disease in terms of crashing and dying suddenly |
| They did not drop to 0 |
Please consider a small donation if you think this website provides you with relevant information